![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPTY2D1 |
Gene summary for SPTY2D1 |
![]() |
Gene information | Species | Human | Gene symbol | SPTY2D1 | Gene ID | 144108 |
Gene name | SPT2 chromatin protein domain containing 1 | |
Gene Alias | Spt2 | |
Cytomap | 11p15.1 | |
Gene Type | protein-coding | GO ID | GO:0001672 | UniProtAcc | Q68D10 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
144108 | SPTY2D1 | LZE4T | Human | Esophagus | ESCC | 2.03e-15 | 3.83e-01 | 0.0811 |
144108 | SPTY2D1 | LZE7T | Human | Esophagus | ESCC | 1.96e-04 | 3.43e-01 | 0.0667 |
144108 | SPTY2D1 | LZE8T | Human | Esophagus | ESCC | 1.23e-03 | 1.53e-02 | 0.067 |
144108 | SPTY2D1 | LZE22T | Human | Esophagus | ESCC | 2.90e-04 | 3.52e-01 | 0.068 |
144108 | SPTY2D1 | LZE24T | Human | Esophagus | ESCC | 2.92e-07 | 2.04e-01 | 0.0596 |
144108 | SPTY2D1 | LZE6T | Human | Esophagus | ESCC | 2.14e-04 | 4.09e-02 | 0.0845 |
144108 | SPTY2D1 | P1T-E | Human | Esophagus | ESCC | 4.60e-03 | 2.52e-01 | 0.0875 |
144108 | SPTY2D1 | P2T-E | Human | Esophagus | ESCC | 8.00e-20 | 3.17e-01 | 0.1177 |
144108 | SPTY2D1 | P4T-E | Human | Esophagus | ESCC | 1.29e-13 | 1.35e-01 | 0.1323 |
144108 | SPTY2D1 | P5T-E | Human | Esophagus | ESCC | 1.74e-13 | 7.71e-02 | 0.1327 |
144108 | SPTY2D1 | P8T-E | Human | Esophagus | ESCC | 4.41e-26 | 5.06e-01 | 0.0889 |
144108 | SPTY2D1 | P9T-E | Human | Esophagus | ESCC | 4.66e-16 | 2.56e-01 | 0.1131 |
144108 | SPTY2D1 | P10T-E | Human | Esophagus | ESCC | 7.54e-14 | 1.83e-01 | 0.116 |
144108 | SPTY2D1 | P11T-E | Human | Esophagus | ESCC | 4.44e-11 | 8.71e-01 | 0.1426 |
144108 | SPTY2D1 | P12T-E | Human | Esophagus | ESCC | 7.80e-09 | 1.74e-01 | 0.1122 |
144108 | SPTY2D1 | P15T-E | Human | Esophagus | ESCC | 9.07e-17 | 2.99e-01 | 0.1149 |
144108 | SPTY2D1 | P16T-E | Human | Esophagus | ESCC | 3.71e-07 | 1.91e-01 | 0.1153 |
144108 | SPTY2D1 | P17T-E | Human | Esophagus | ESCC | 7.04e-06 | 2.38e-01 | 0.1278 |
144108 | SPTY2D1 | P20T-E | Human | Esophagus | ESCC | 3.22e-14 | 2.43e-01 | 0.1124 |
144108 | SPTY2D1 | P21T-E | Human | Esophagus | ESCC | 3.84e-16 | 2.10e-01 | 0.1617 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:0043486 | Esophagus | ESCC | histone exchange | 16/8552 | 22/18723 | 9.46e-03 | 3.28e-02 | 16 |
GO:19022751 | Esophagus | ESCC | regulation of chromatin organization | 22/8552 | 33/18723 | 1.22e-02 | 4.08e-02 | 22 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
GO:000633813 | Thyroid | ATC | chromatin remodeling | 109/6293 | 255/18723 | 1.38e-03 | 7.15e-03 | 109 |
GO:00718242 | Thyroid | ATC | protein-DNA complex subunit organization | 103/6293 | 241/18723 | 1.84e-03 | 9.03e-03 | 103 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPTY2D1 | SNV | Missense_Mutation | rs200478855 | c.170N>A | p.Arg57Gln | p.R57Q | Q68D10 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPTY2D1 | SNV | Missense_Mutation | c.265A>G | p.Thr89Ala | p.T89A | Q68D10 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AR-A1AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
SPTY2D1 | SNV | Missense_Mutation | novel | c.1889N>G | p.Tyr630Cys | p.Y630C | Q68D10 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPTY2D1 | SNV | Missense_Mutation | novel | c.1561N>T | p.Gly521Trp | p.G521W | Q68D10 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-WT-AB41-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
SPTY2D1 | SNV | Missense_Mutation | novel | c.457N>A | p.Glu153Lys | p.E153K | Q68D10 | protein_coding | tolerated(0.61) | benign(0.15) | TCGA-WT-AB41-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
SPTY2D1 | SNV | Missense_Mutation | rs144792493 | c.409N>A | p.Ala137Thr | p.A137T | Q68D10 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SPTY2D1 | SNV | Missense_Mutation | novel | c.598G>A | p.Glu200Lys | p.E200K | Q68D10 | protein_coding | deleterious(0.05) | benign(0.197) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
SPTY2D1 | SNV | Missense_Mutation | rs569563128 | c.1580N>T | p.Ser527Leu | p.S527L | Q68D10 | protein_coding | tolerated(0.2) | possibly_damaging(0.637) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
SPTY2D1 | SNV | Missense_Mutation | novel | c.1064C>T | p.Pro355Leu | p.P355L | Q68D10 | protein_coding | tolerated(0.15) | benign(0) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
SPTY2D1 | SNV | Missense_Mutation | c.662N>T | p.Gly221Val | p.G221V | Q68D10 | protein_coding | tolerated(0.28) | benign(0) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |